R ice regimen for lymphoma

    • [PDF File]NHL Fractionated R-ICE G

      https://info.5y1.org/r-ice-regimen-for-lymphoma_1_4e25e9.html

      G:\Division\HAE\REDBOOK\Chemotherapy Prescriptions\NHL\Fractionaeted ICE + GCSF ± Rituximab Review due: September 2020 C H E M O T R A P Y E T T M D I C I O N C H A R C 2 6 0 7 Non Hodgkins Lymphoma (NHL) Fractionated ICE + GCSF (± Rituximab) Height cm Attach patient label Weight kg BSA m2

    • [PDF File]ESHAP and R-ESHAP

      https://info.5y1.org/r-ice-regimen-for-lymphoma_1_d19122.html

      ESHAP and R-ESHAP [This regimen can be delivered during an inpatient stay or can be used in ambulatory setting for patient(s) meeting the criteria. Refer to local Ambulatory Care Operational Policy] INDICATIONS LYMPHOMA [ICD-10 codes: C.81, C.85] ESHAP: Chemo-sensitive relapsed / refractory Hodgkin lymphoma (Licensed indication (E),

    • [PDF File]NON-HODGKIN LYMPHOMA TREATMENT REGIMENS: Burkitt Lymphoma (Part 1 of 3)

      https://info.5y1.org/r-ice-regimen-for-lymphoma_1_35d1c5.html

      non-Hodgkin lymphoma and mature B-cell acute lympho - blastic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2009;52:177–181. 11. Fan Y, Huang ZY, Luo LH, Yu HF. Efficacy of GDP regimen on relapsed or refractory aggressive non-Hodgkin’s lymphoma: a report of 24 cases. Ai Zheng. 2008;27(11):1222–1225. 12.

    • [PDF File]Chemotherapy regimen: ICE

      https://info.5y1.org/r-ice-regimen-for-lymphoma_1_775865.html

      toxicity shown in CDE regimen and PI-based regimen (infections, neutropenia, mucositis) (4, 5). Good tolerability in three cases with lopinavir/ritonavir and either DA-EPOCH or CODOX-M/IVAC for treatment of non-Hodgkin’s lymphoma or Hodgkin’s lymphoma, respectively.(8, 9) Carboplatin Main route of elimination is renal. Pharmacokinetic

    • [PDF File]NCCP Chemotherapy Regimen R-CEOP Therapy 21 days - Health Service Executive

      https://info.5y1.org/r-ice-regimen-for-lymphoma_1_feb617.html

      NCCP Chemotherapy Regimen NCCP Regimen:R-CEOP Therapy Published: 15/02/2019 Review: 03/02/2026 Version number:2 Tumour Group: Lymphoma NCCP Regimen Code: 00510 IHS Contributor: Dr Derville O’Shea ISMO Contributor : Prof Maccon Keane Page 1 of 8 The information contained in this document is a statement of consensus of NCCP and ISMO or IHS ...

    • Non-Hodgkin Lymphoma SUPPLEMENTARY A Early treatment intensification ...

      Non-Hodgkin Lymphoma SUPPLEMENTARY APPENDIX Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk ... R-ICE Regimen The R-ICE salvage regimen consisted of rituximab 375mg/m2, ifosfamide 5 000 mg/m2, carboplatin AUC = 5 [maximum 800 mg], ...

    • [PDF File]Chemotherapy Protocol LYMPHOMA CARBOPLATIN-ETOPOSIDE-IFOSFAMIDE (ICE ...

      https://info.5y1.org/r-ice-regimen-for-lymphoma_1_651c6e.html

      Lymphoma-InP-ICE-Carboplatin-Etoposide-Ifosfamide Regimen 3 cycles (1 cycle will be set in Aria) Drug Dose Days Administration Carboplatin AUC 5 (max 800mg) 2 Intravenous infusion in 500ml glucose 5% over 60 minutes Etoposide 100mg/m2 1,2,3 Intravenous infusion in 1000ml sodium chloride 0.9% over 60 minutes Mesna 21000mg/m 2

    • [PDF File]R-GDP: Rituximab, Gemcitabine, Dexamethasone &Cisplatin

      https://info.5y1.org/r-ice-regimen-for-lymphoma_1_264969.html

      Lymphoma group This is a controlled document and therefore must not be changed or photocopied L.62 R-GDP Authorised by Lymphoma lead Dr. Graham Collins Date: May 2018 Published: July 2016 Reviewed: Aug 2020 Review: May 2022 Version 1.2 6 of 5 NURSING CARE PLAN R-GDP Indication: Relapsed or refractory Hodgkin and non-Hodgkin lymphoma.

    • [PDF File]NCCP Chemotherapy Regimen (R*)- ESHAP Therapy - Health Service Executive

      https://info.5y1.org/r-ice-regimen-for-lymphoma_1_38c4d2.html

      Tumour Group: Lymphoma NCCP Regimen Code: 00394 IHS Contributors: Prof Elisabeth Vandeberghe Page 1 of 5 The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is ...

    • [PDF File]NSSG Chemotherapy Protocol

      https://info.5y1.org/r-ice-regimen-for-lymphoma_1_676320.html

      Lymphoma group This is a controlled document and therefore must not be changed or photocopied L.24 R-ICE Authorised by Lymphoma lead Prof Graham Collins Date: July 2022 Published: July 2022 Review: July 2024 Version 2.0 5 of 9 EMETIC RISK Day 1: Low Day 2: High Day 3: Moderate ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS

    • [PDF File]NCCP Regimen 00397 (R*)-ICE ((rRiTUXimab), Ifosfamide, CARBOplatin and ...

      https://info.5y1.org/r-ice-regimen-for-lymphoma_1_977f91.html

      NCCP Chemotherapy Regimen NCCP Regimen: (R)ICE Therapy Published: 28/07/2017 Review: 21/09/2027 Version number: 3 Tumour Group: Lymphoma NCCP Regimen Code: 00397 IHS/ISMO Contributors: Prof Elisabeth Vandenberghe, Prof Maccon Keane Page 2 of 9

    • [PDF File]CHOEP Therapy– 21 days - Health Service Executive

      https://info.5y1.org/r-ice-regimen-for-lymphoma_1_a285d9.html

      high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2008;19(3):545-552. 3. Schmitz N, Trümper L, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.

    • [PDF File]NSSG Chemotherapy Protocol

      https://info.5y1.org/r-ice-regimen-for-lymphoma_1_20bcb7.html

      Chemotherapy in Patients with Diffuse Large B Cell Lymphoma. Biol Blood Marrow Transplant 2016. 22(8):1397-1402. 2. Gisselbrecht C et al. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study. Journal of Clinical Oncology 2009. 27(15S):8509-8509. 3.

    • How I manage patients with relapsed/refractory diffuse large B cell ...

      seem, in the first relapse, to be different from one regimen to another (Gisselbrecht et al, 2010). The Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL) study was a phase III, multicentre, randomized trial that compared the efficacy of 3 R-ICE or R-DHAP cycles followed by ASCT with or without rituximab mainte-

    • Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy ...

      We have sought to improve on the ICE regimen by the addition of rituximab (R-ICE). In the following update, the results of the ICE regimen for 222 patients treated over 7 years, now with 5 years median follow-up for surviving patients, are presented. The ICE regimen remains an excellent second-line chemotherapy approach, with short-

    • [PDF File]NCCP Chemotherapy Regimen (R*)-DHAP Therapy - Health Service Executive

      https://info.5y1.org/r-ice-regimen-for-lymphoma_1_bdecc5.html

      NCCP Chemotherapy Regimen NCCP Regimen:(R*)-DHAP Therapy Published: 28/07/2017 Review: 27/06/2027 Version number: 3 Tumour Group: Lymphoma NCCP Regimen Code: 00395 IHS /ISMO Contributors: Prof Elisabeth Vandenberghe Prof Maccon Keane Page 1 of 6 The information contained in this document is a statement of consensus of NCCP and ISMO or IHS ...

Nearby & related entries:

To fulfill the demand for quickly locating and searching documents.

It is intelligent file search solution for home and business.

Literature Lottery

Advertisement
Hot searches

©2024 5y1.org, Inc. All rights reserved.